Theurapeutic Areas

Cancer is among the leading causes of death globally. According to WHO, it takes around 10 million lives each year, and often it occurs due to inaccessible diagnosis and treatment. In BIOCAD we believe that accessible drugs are crucial to fighting cancer.

Therefore, we work hard on providing high-quality biosimilars and generics, as well as original therapeutics for lymphomas and lung, colorectal, breast and gynecological cancers. Diversity is one of the main weapons of cancer, and our drugs contribute to disarming it.

The latest reports show growing numbers of people affected by numerous diseases caused by malfunctions of the immune system. Among the most common are psoriasis, rheumatoid arthritis and ankylosing spondylitis.

So far medicine cannot fully treat all autoimmune disorders, but we are making all possible efforts to provide significant and stable improvements for people living with them.

Orphan (rare) diseases are diseases that occur in a small percentage of general population; 6000 to 8000 of them are known to date. About 80% of those diseases are hereditary, caused by gene or chromosomal mutations; the rest are rare forms of cancer or viral or bacterial infections. It takes 6-8 years on average to receive a reliable diagnosis, while patients undergo various tests and receive several misdiagnoses. And then, unfortunately, for most orphan diseases there is currently no effective treatment.

BIOCAD is committed to developing biologics and gene therapy products not only to extend life, but to completely cure patients with SMA, neuroblastoma and other rare diseases.